Literature DB >> 30197026

Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications.

S Bockel1, B Durand2, E Deutsch3.   

Abstract

Besides its direct cytotoxic effect on the tumor cells, radiation therapy is also able to elicit an immune-mediated systemic anti-tumor response, resulting in tumor regression in irradiated sites but also within distant out of field secondary lesions and providing a long-term anti-tumor response. It is now clear that associating ionizing radiation with immune therapies can enhance radio-induced anti-tumor immune responses. Over the last decade, such a combination aroused considerable interest among the scientific community, with many preclinical models and clinical trials, using many types of immune therapies and radiation regimens. In this article, we summarize the main mechanisms underlying radio-induced anti-tumor responses. We will then present an extended overview of the recent preclinical and clinical research built on this background of combined radiation and immune therapy, shedding light on what we know so far about such a promising strategy.
Copyright © 2018. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Abscopal effect; Anti-tumor immunity; Effet abscopal; Immunité anti tumorale; Immunogenic cell death; Immunotherapy; Immunothérapie; Mort cellulaire immunogène; Radiotherapy; Radiothérapie

Mesh:

Year:  2018        PMID: 30197026     DOI: 10.1016/j.canrad.2018.07.136

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  8 in total

Review 1.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 2.  Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.

Authors:  Chen Chen; Yanlong Liu; Binbin Cui
Journal:  Hum Vaccin Immunother       Date:  2021-01-11       Impact factor: 3.452

3.  Caffeic Acid Phenethyl Ester-Incorporated Radio-Sensitive Nanoparticles of Phenylboronic Acid Pinacol Ester-Conjugated Hyaluronic Acid for Application in Radioprotection.

Authors:  Seon-Hee Choi; Dong-Yeon Lee; Sohi Kang; Min-Kyung Lee; Jae-Heun Lee; Sang-Heon Lee; Hye-Lim Lee; Hyo-Young Lee; Young-Il Jeong
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

Review 4.  Radiation-induced bystander and abscopal effects: important lessons from preclinical models.

Authors:  Elisabeth Daguenet; Safa Louati; Anne-Sophie Wozny; Nicolas Vial; Mathilde Gras; Jean-Baptiste Guy; Alexis Vallard; Claire Rodriguez-Lafrasse; Nicolas Magné
Journal:  Br J Cancer       Date:  2020-06-25       Impact factor: 7.640

5.  Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.

Authors:  Danni Xie; Xin Jin; Rui Sun; Meng Zhang; Jiaxi Wang; Xia Xiong; Xiaomei Zhang; Mingfeng Zhao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study.

Authors:  Luc Ollivier; Charles Orione; Paul Bore; Laurent Misery; Delphine Legoupil; Jean-Christophe Leclere; Anne Coste; Gilles Girault; Iona Sicard-Cras; Clemence Kacperek; Francois Lucia; Dinu Stefan; François Thillays; Emmanuel Rio; Paul Lesueur; Christian Berthou; Dominique Heymann; Stéphane Champiat; Stéphane Supiot; Loig Vaugier; William Kao
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

7.  Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study).

Authors:  Tadaaki Yamada; Junji Uchino; Yusuke Chihara; Takayuki Shimamoto; Masahiro Iwasaku; Nobuyo Tamiya; Yoshiko Kaneko; Fumiaki Kiyomi; Koichi Takayama
Journal:  Ther Adv Med Oncol       Date:  2020-05-28       Impact factor: 8.168

8.  Targeting the Innate Immune Kinase IRAK1 in Radioresistant Cancer: Double-Edged Sword or One-Two Punch?

Authors:  Peter H Liu; Samuel Sidi
Journal:  Front Oncol       Date:  2019-11-13       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.